{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:11:05Z","timestamp":1790727065156,"version":"4.1.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pyoderma gangrenosum (PG) is a rare, chronic neutrophilic dermatosis characterized by rapidly progressive, painful ulcers. It is frequently associated with systemic inflammatory conditions such as inflammatory bowel disease. The pathogenesis remains incompletely understood, and treatment of refractory cases poses a significant challenge. We present a 26-year-old woman diagnosed with PG, initially managed with systemic corticosteroids and ciclosporin. During follow-up, she developed gastrointestinal symptoms and was subsequently diagnosed with Crohn disease (CD). Despite treatment with azathioprine, infliximab and, later, ustekinumab, the patient experienced repeated flares of both PG and CD. Upon recurrence of PG lesions and CD exacerbation under ustekinumab therapy, systemic corticosteroids were reintroduced, and subcutaneous guselkumab, an interleukin (IL)-23 p19 inhibitor, was initiated. A rapid and sustained clinical response was observed following the second dose of guselkumab, with complete ulcer healing and tapering off corticosteroids. The patient has remained in complete remission from both PG and CD for over 2 years under guselkumab monotherapy. This case adds to the growing body of evidence supporting the use of IL-23 inhibitors, particularly guselkumab, in recalcitrant PG associated with systemic inflammatory comorbidities. Guselkumab may offer a promising therapeutic alternative in the management of treatment-resistant PG, especially in patients with coexisting CD.<\/jats:p>","DOI":"10.1093\/skinhd\/vzag103","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:38:46Z","timestamp":1783532326000},"page":"812-815","source":"Crossref","is-referenced-by-count":0,"title":["Guselkumab as a therapeutic option for recalcitrant pyoderma gangrenosum and Crohn disease: a case report and review of the literature"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6423-6272","authenticated-orcid":false,"given":"Mahmut Esat","family":"Tanr\u0131bilir","sequence":"first","affiliation":[{"name":"Department of Dermatology, Ministry of Health Ilg\u0131n Dr. Vefa Tan\u0131r State Hospital , Konya ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2185-6222","authenticated-orcid":false,"given":"Osmanege","family":"Atliya","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Gazi University Faculty of Medicine , Ankara ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarkan","family":"Karakan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology, Gazi University Faculty of Medicine , Ankara ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Ad\u0131\u015fen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Gazi University Faculty of Medicine , Ankara ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"2026092919520488200_vzag103-B1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/1346-8138.17031","article-title":"New treatment of pyoderma gangrenosum and hidradenitis suppurativa: a review","volume":"51","author":"Yamanaka","year":"2024","journal-title":"J Dermatol"},{"key":"2026092919520488200_vzag103-B2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-023-01931-3","article-title":"Pyoderma gangrenosum: treatment options","volume":"83","author":"Dissemond","year":"2023","journal-title":"Drugs"},{"key":"2026092919520488200_vzag103-B3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41572-020-0213-x","article-title":"Pyoderma gangrenosum","volume":"6","author":"Maverakis","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2026092919520488200_vzag103-B4","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/s41590-019-0514-y","article-title":"IL-17 receptor-based signaling and implications for disease","volume":"20","author":"Li","year":"2019","journal-title":"Nat Immunol"},{"key":"2026092919520488200_vzag103-B5","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/archdermatol.2011.168","article-title":"Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab","volume":"147","author":"Guenova","year":"2011","journal-title":"Arch Dermatol"},{"key":"2026092919520488200_vzag103-B6","doi-asserted-by":"crossref","first-page":"15859","DOI":"10.2147\/JIR.S540840","article-title":"Pyoderma gangrenosum and inflammatory bowel disease: recent insights into epidemiology, pathogenesis, and therapeutic approaches","volume":"18","author":"Downey","year":"2025","journal-title":"J Inflamm Res"},{"key":"2026092919520488200_vzag103-B7","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jaad.2021.05.006","article-title":"Prevalence of inflammatory bowel disease in patients with pyoderma gangrenosum: a population-based analysis","volume":"86","author":"Xu","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2026092919520488200_vzag103-B8","doi-asserted-by":"crossref","DOI":"10.3390\/ph18040447","article-title":"New interleukin-23 antagonists\u2019 use in Crohn\u2019s disease","volume":"18","author":"Biskup","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026092919520488200_vzag103-B9","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13010224","article-title":"The role of IL-23 inhibitors in Crohn\u2019s disease","volume":"13","author":"Fanizza","year":"2023","journal-title":"J Clin Med"},{"key":"2026092919520488200_vzag103-B10","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7861\/clinmedicine.19-3-224","article-title":"Pyoderma gangrenosum \u2013 a guide to diagnosis and management","volume":"19","author":"George","year":"2019","journal-title":"Clin Med (Lond)"},{"key":"2026092919520488200_vzag103-B11","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40257-022-00699-8","article-title":"Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments","volume":"23","author":"Maronese","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"2026092919520488200_vzag103-B12","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2436015","article-title":"Off-label dermatologic uses of IL-23 inhibitors","volume":"35","author":"Porter","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"2026092919520488200_vzag103-B13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jvc2.522","article-title":"Successful treatment of pyoderma gangrenosum with guselkumab","volume":"4","author":"Botvid","year":"2024","journal-title":"JEADV Clin Pract"},{"key":"2026092919520488200_vzag103-B14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jdcr.2021.11.030","article-title":"Modified dose of guselkumab for treatment of pyoderma gangrenosum","volume":"21","author":"Reese","year":"2022","journal-title":"JAAD Case Rep"},{"key":"2026092919520488200_vzag103-B15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jdcr.2020.12.005","article-title":"Guselkumab as a treatment option for recalcitrant pyoderma gangrenosum","volume":"8","author":"Baier","year":"2021","journal-title":"JAAD Case Rep"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/5\/812\/68721651\/vzag103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/5\/812\/68721651\/vzag103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:52:11Z","timestamp":1790725931000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/6\/5\/812\/8728481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,7,8]]},"published-print":{"date-parts":[[2026,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/skinhd\/vzag103","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,7,8]]}}}